Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort.

PLoS One · 2025 · PMC11709318 · PMID 39774438

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Median PCS scores showed a trend for improvement at 12 months, although the change was not statistically significant (median [Q1, Q3] change: +2.1 [−1.0, 3.9]; p = 0.1442) ( S6 Table ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.